RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA

Objective: to study the efficiency and tolerance of rituximab (RTM) treatment in patients with scleroderma systematica (SDS) with interstitial lung injury (ILI).Subjects and methods. The trial included 27 patients (26 women and 1 man) (mean age 45.7±13.0 years), with diffuse (n=13) and circumscribed...

Full description

Bibliographic Details
Main Authors: Lidia Petrovna Ananieva, O V Desinova, O A Koneva, M N Starovoitova, N N Yutkina, A V Volkov, O B Ovsyannikova, A P Aleksankin, E N Aleksandrova, A A Novikov, E L Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2013-12-01
Series:Научно-практическая ревматология
Subjects:
scleroderma systematica
rituximab
forced vital capacity
diffusing capacity
b lymphocytes
depletion
Online Access:https://rsp.mediar-press.net/rsp/article/view/1337

Internet

https://rsp.mediar-press.net/rsp/article/view/1337

Similar Items